ENVERIC BIOSCIENCES INC (ENVB) Stock News

NASDAQ:ENVB - US29405E4061 - Common Stock

1.22 USD

+0.06 (+5.01%)

Last: 8/22/2025, 8:04:56 PM

1.22 USD

0 (0%)

After Hours: 8/22/2025, 8:04:56 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ENVB Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Enveric Biosciences

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

a month ago - By: Enveric Biosciences

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

a month ago - By: Enveric Biosciences

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

2 months ago - By: Enveric Biosciences

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

2 months ago - By: Enveric Biosciences

Enveric Biosciences Announces Participation in 2025 BIO International Convention

3 months ago - By: Enveric Biosciences

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

3 months ago - By: Enveric Biosciences

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

3 months ago - By: Enveric Biosciences

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

3 months ago - By: Enveric Biosciences

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

3 months ago - By: Benzinga - Mentions: DRRX SSII RAPT HCTI ...

12 Health Care Stocks Moving In Friday's After-Market Session

3 months ago - By: Enveric Biosciences

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

4 months ago - By: Benzinga - Mentions: PTIX ANVS MEDP PRPO ...

12 Health Care Stocks Moving In Monday's After-Market Session

5 months ago - By: Enveric Biosciences

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

5 months ago - By: Enveric Biosciences, Inc.

Enveric Biosciences Participating in BIO-Europe Spring®

6 months ago - By: Enveric Biosciences

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

6 months ago - By: Enveric Biosciences

Enveric Biosciences CEO Issues Letter to Shareholders

6 months ago - By: Enveric Biosciences

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

7 months ago - By: Enveric Biosciences

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

7 months ago - By: Enveric Biosciences, Inc.

Enveric Biosciences Announces Closing of $5 Million Public Offering